**EliA™ PM-Scl**

*Safer differential diagnosis of connective tissue diseases*

**Whom to test?**
- Subjects in whom polymyositis/scleroderma (PM/SSc) overlap syndrome is suspected.
- Subjects in whom scleroderma or childhood scleromyositis is suspected.
- Subjects with unspecific symptoms, when differential diagnosis of myositis of unclear origin is the issue.
- Patients showing symptoms of the myositis/scleroderma disease area, such as muscle weakness combined with elevated CK, lung fibrosis or Raynaud’s phenomenon.

**Why to test?**
- Guidance in diagnostic decisions: PM-Scl antibodies are a specific marker for PM/SSc overlap syndrome.
- Useful for difficult differential diagnosis: PM-Scl antibodies occur in app. 24% of patients with PM/SSc overlap syndrome, but in only app. 3% of patients with scleroderma.
- High clinical value of a positive result: App. 70% of PM-Scl-positive patients have PM/SSc overlap syndrome, app. 20% have idiopathic myositis and app. 10% have scleroderma.
- Prognostic value: Cardiac and renal involvement is very rare in PM-Scl positive patients (1-3%). Such patients have a relatively good prognosis.

**When to test?**
- If a positive result in indirect immunofluorescence on HEp-2 cells shows a nucleolar pattern – then in combination with other markers
- In case of a positive EliA CTD Screen result – then in combination with other markers

**Why EliA PM-Scl?**
- First fully automated PM-Scl antibody test worldwide – saves time and money
- All EliA tests, from the EliA CTD Screen down to 16 single analyte ANA tests can be performed on the same instruments (Phadia 100, 250, 2500 and 5000) which are designed to fit every lab size.
- Delivers simple and fast results, independent of numbers of samples – best service to clinicians
- Almost no false positive results – high clinical usefulness
Performance of EliA™ PM-Scl

Samples from 30 patients with PM/SSc overlap syndrome, 40 patients with polymyositis/dermatomyositis, 80 patients with scleroderma and 200 control patients with other diseases (connective tissue diseases, rheumatoid arthritis, infections, tumors) were investigated.

EliA PM-Scl is sensitive in detecting PM/SSc overlap syndrome

The test sensitivity of 20 % for PM/SSc overlap syndrome is in the range reported in the literature1 (Fig 1.), and ~70% of positive patients have that disease entity or closely related entities1.

EliA PM-Scl is very specific and gives results of high clinical value

The test specificity in diseased control patients is very high, assuring a high positive predictive value (PPV) and a high positive likelihood ratio (LR+) of the results (Table 1). This gives positive test results a high clinical value in diagnostic decisions.

Ordering information

Product                        Article number  Content
EliA™ PM-Scl Well              14-5602-01  24 determinations

For general reagents please see Phadia Autoimmunity Product Catalog.

References